take last train memphi
thesi updat week earn result brought
rare ray sunshin pharma suppli chain
part today solid oper ep beat even adjust
opex save pull-forward woo woo
insert simul train nois addit final
lap neg pharmedium impact although updat
isnt super encourag one like sizeabl write-down
oper perform current repo
author estim broadli move higher
thing said distributor wood
mean potenti chang rebat opioid litig
worsen financi distributor profit
custom remain signific cloud horizon
navig abli suppli chain
challeng continu weigh valuat continu
see strateg action less like thu
rais estim account improv oper
perform maintain rate
evercor isi grate consider ross
muken healthcar distribut
click link confer call summary/guid
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
pharmedium expect headwind mm
march quarter last quarter major hit
saw opex off-set pullforward ep
origin expect hit
anticip solid mwi growth despit growth weather hit product busi
chang pharmaceut price expect full fiscal year
share count mm share mm
spread rel constant
less like low end ep rang given business/market perform outlook
would move low end would worsen situat memphi
potenti futur share repurchas includ guidanc
purchas mm share quarter mm remain current author
purchas mm last quarter
move busi open facil
expect enter consent decre june quarter
allow commerci distribut continu open facil
specifi requir must satisfi prior reopen memphi facil
sharehold vetsourc happi result
also offer value-ad servic
still transit year lash busi develop go well fusion-driven
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti resumpt independ price war result materi margin degrad
signific profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin
result overal compress increment soft pharmedium growth lessen inflat continu challeng
relat revamp qc process polit threat chang rx price methodolog gross net intens scrutini
opioid curtail distribut profit execut challeng onboard hd smith asset potenti leakag key
independ custom transit period inabl transit specialti contract long term new econom
allow fair payment differenti servic
laboratori corp america
articl articl
time dissemin may
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
